



A recognized complication of allogeneic stem cell trans-
plantation is acute graft-versus-host disease (aGVHD). The
primary target organs for aGVHD are the skin, the liver, and
the bowel; the reason these organs are the targets for this
immune reaction continues to merit investigation. A pro-
posed pathophysiologic mechanism is that these organs have
minor histocompatibility antigens that are capable of being
presented to effector immune cells, leading to the GVHD
reaction. Goulmy and colleagues [1,2] have clearly shown that
minor histocompatibility antigens cause skin GVHD and that
limited tissue distribution of a minor histocompatibility anti-
gen can lead to a speciﬁc graft-versus-leukemia effect [1,2].
An important clinical observation is that individuals
develop different patterns of aGVHD. Not all people with
skin GVHD, for example, develop liver or bowel GVHD.
Similarly, patients who develop bowel or liver GVHD do not
necessarily develop skin GVHD. We observed an intriguing
clinical course of initial skin aGVHD followed by liver
aGVHD. We hypothesized that, during clinical GVHD, T-cell
inﬁltrates within a liver biopsy would show a restricted T-cell
response because the T cells would be responding to a lim-
ited number of tissue-specific antigens. In this case report
supported with immunologic data, we demonstrate that dur-
ing an episode of acute liver GVHD, there is a limited T-cell
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ABSTRACT
Data from animal models have shown that hepatic graft-versus-host disease (GVHD) may be mediated by donor
T cells interacting with liver adhesion molecules, other minor histocompatibility antigens, or both. We hypothe-
sized that T-cell infiltrates within a liver biopsy during clinical GVHD would show a restricted T-cell response
because the T cells would be responding to a limited number of antigens. We studied the peripheral T-cell reper-
toire and the liver-infiltrating T-cell repertoire of a patient who developed skin GVHD and subsequent liver GVHD
after a matched sibling bone marrow transplantation for acute myeloid leukemia. Spectratype analysis of peripheral
blood at the time of liver GVHD revealed that the patient had reconstituted a complex peripheral T-cell repertoire
as evidenced by the presence of complementarity-determining region 3 (CDR3) length heterogeneity in most of the
T-cell families. The repertoire complexity was skewed in variable gene beta (VΒ) 5.3, VB4, VB7, VB8, and VB15.
Spectratype analysis on the liver biopsy sample revealed a limited infiltrate with an oligoclonal expansion in VBs 4,
7, and 8. We evaluated the T-cell infiltrate in more detail by sequencing the relevant expansions noted by spec-
tratype and developing probes for the predominant CDR3 sequences. These clonotype probes were hybridized to
peripheral blood and liver samples from the patient, a T-cell line developed from the patient’s peripheral blood at
the time of the initial skin GVHD, the donor’s blood and marrow, and control samples. The results showed that the
T-cell infiltrate during liver GVHD is mediated by a limited number of T cells, and that those cells are mostly dif-
ferent from the ones expanded from the peripheral blood during an acute skin GVHD reaction. These data support
the concept that liver GVHD is a response to tissue-specific minor histocompatibility antigens.
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infiltrate within the liver. These data support the concept
that tissue-speciﬁc antigens contribute to GVHD in humans.
CLINICAL HISTORY
The patient, a 14-year-old boy, was diagnosed with
stage M4 acute myeloid leukemia. Remission was induced
with daunomycin, cytosine arabinoside, and 6-thioguanine.
After a single course of consolidation chemotherapy with
high-dose cytosine arabinoside, the patient proceeded to
allogeneic bone marrow transplantation (BMT) in ﬁrst com-
plete remission. After a conditioning regimen of 12 Gy total
body irradiation and 60 mg/kg etoposide as a 4-hour infu-
sion, he received a T cell–replete allograft of 2.5 × 108
mononuclear cells per kg from his HLA-matched 12-year-
old sister. GVHD prophylaxis consisted of standard short-
course methotrexate combined with cyclosporine (CsA).
The initial posttransplantation course was complicated by
mucositis, fever, and a skin rash presenting on day 20. A clini-
cal diagnosis of grade III skin GVHD was made by the trans-
plant team with dermatology consultation. The patient was
treated with a short course of antithymocyte globulin (ATG)
(Upjohn, Bridgwater, NJ) 15 mg/kg per day and methylpred-
nisolone 2 mg/kg per day for 4 days. A skin biopsy was not
done at the time because of the clear diagnosis of GVHD and
the patient’s serious condition. However, a blood sample was
taken to establish a T-cell line from cells circulating at the
time of skin GVHD. The fevers and rash subsided with initi-
ation of treatment, and the patient was well enough to be dis-
charged on day 30 posttransplantation. He had no symptoms
of bowel or liver GVHD during his initial hospital stay.
The patient was weaned off steroids by day 40, and CsA
was being tapered when he developed elevations in serum
transaminases at day 70. By day 80, alanine aminotransferase
(ALT) increased to 2500 IU/L (more than 10 times normal),
aspartate aminotransferase (AST) increased to 1077 IU/L
(more than 10 times normal), and γ-glutamyl transferase
increased to 1300 IU/L (more than 10 times normal), yet
alkaline phosphatase at 200 IU/L and bilirubin at 0.9 mg/dL
were normal. He had no clinical manifestations of gastroin-
testinal or skin GVHD. Because of the unclear clinical pic-
ture of transaminase elevation without evidence suggesting
cholestatic jaundice, an open liver biopsy was performed.
The histologic picture was consistent with GVHD of the
liver. Additional immunosuppressive therapy was given with
ATG, glucocorticoids, and tacrolimus replacing the CsA.
The transaminases improved and he was placed on
monotherapy with tacrolimus. Initial attempts to wean him
from tacrolimus 3 months after the initial episode of liver
GVHD (6 months after transplantation) resulted in liver
enzyme abnormalities, which corrected with increased
immunosuppression. Over the next 9 months, he tolerated a
slow reduction of the immunosuppression, with cessation of
therapy at 16 months posttransplantation. Six weeks after
discontinuing immunosuppression, his transaminases again
rose to 4 times normal and then improved to 2 times normal
over a 6-week period without intervention. He had normal
levels of bilirubin, alkaline phosphatase, and lactate dehydro-
genase. Repeated tests for hepatitis B and C were negative.
Throughout his course, the patient exhibited 100% donor
chimerism in all peripheral blood and bone marrow samples.
MATERIALS AND METHODS
The methodology of spectratyping and clonotyping is
summarized in Figure 1. The techniques were most recently
described by Bacsi et al. [3]
Patient and donor samples were obtained under an
Institutional Review Board–approved protocol. Peripheral
blood mononuclear cells (PBMCs) obtained from whole cit-
rate blood were isolated by Ficoll-Hypaque gradient and
used throughout this procedure. Liver tissue was frozen at
the time of biopsy to be used later. Routine histologic analy-
sis, including hematoxylin and eosin staining and immuno-
histochemistry using anti-CD4+ and anti-CD8+ stains, was
done by the pathology department at the Children’s Hospi-
tal of Wisconsin (Milwaukee, WI).
Samples studied for spectratyping and clonotyping con-
sisted of complementary DNA (cDNA) derived from the
liver biopsy, peripheral blood taken at the time of liver
GVHD, peripheral blood taken 17 months after the trans-
plantation, donor marrow and peripheral blood from the
time of donation, and the T-cell line developed from cells
circulating at the time of the initial skin GVHD. The T-cell
line was derived from a protocol by Coligan et al. [4], with
modifications. Briefly, PBMCs were isolated by Ficoll-
Hypaque, washed, and counted. Cells were suspended in
RPMI, penicillin/streptomycin, HEPES, L-glutamine, 10%
fetal bovine serum, and 100 U/mL human recombinant
interleukin-2 (rIL-2 medium) supplemented with 5 µg/mL
phytohemagglutinin (PHA) for 3 days at a concentration of
1 × 106 cells/mL. After 3 days, cells were washed to remove
excess PHA and resuspended in rIL-2 medium. Cultures
were fed with rIL-2 medium twice a week and grown until
an adequate number of cells were present.
RNA and cDNA Preparation
RNA was prepared using Trizol reagent (Gibco/Life
Technologies, Rockville, MD). Total RNA (1 µg) was con-
verted into cDNA using oligo(dT) as primer for reverse
transcription as described by Maslanka et al [5].
Polymerase chain reaction amplification. Polymerase chain
reaction (PCR) amplification was performed according to
Maslanka et al. [5]. Briefly, cDNA was amplified for 30
cycles under nonsaturating PCR conditions with a panel of
T-cell receptor β-chain variable gene (TCR BV) family–spe-
cific primers and a β-chain constant primer in duplex or
simplex (for BV 6.1 and 6.2) reactions using 24 TCR BV
family–speciﬁc primers and pairings. The common constant
primer was labeled at the 5′ end with 5′-6 carboxyﬂuores-
cein (6-FAM). In addition to the TCR BV family–specific
and constant primers, each reaction contained an actin-
specific primer pair producing a 6-FAM–labeled 230–base
pair (bp) product as an internal PCR control for veriﬁcation
of cDNA integrity and fidelity of PCR reactions. The
β-actin primer sequences, 5′-CCCTGTACGCCTCTGGC
CGTACCAC-3′ (6-FAM–labeled) and 5′-CACGGCATCG
TCACCAACTGGG-3′, were added to a final concentra-
tion of 0.025 µmol/L.
TCR spectratyping. TCR spectratyping was performed as
described by Maslanka et al. [5] Briefly, an equivalent vol-
ume of PCR-labeled product was mixed with formamide
dye-loading buffer, heated at 94°C for 2 minutes, and
applied to a pre-run 5% acrylamide-urea sequencing gel.
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Gels were run for 110 minutes at 40 W. After resolution
on the gel, the labeled PCR product was analyzed with a
Molecular Dynamics FluorImager 575 (Sunnyvale, CA).
TCR spectratyping of a healthy PBMC repertoire typically
results in a banding pattern of 7 or 8 bands at 3–nucleotide
base intervals, reflecting the correct “in-frame” nature of
functionally rearranged β-chain TCR gene products. The
limited number of PCR cycles used (30) leads to the gener-
ation of PCR products with a distribution representative of
the starting material, ie, a Gaussian distribution. Each
band in a spectratype, while uniform in size, is heteroge-
neous with respect to the nucleotide sequences it contains,
as would be expected given the high degree of diversity
required of TCR complementarity-determining region 3
(CDR3) regions.
PCR product cloning and DNA sequencing. The TCR
β-chain PCR products corresponding to specific spec-
tratype bands were cloned using a T/A Cloning Kit (Invit-
rogen, San Diego, CA) for PCR fragment cloning. Entire
PCR reactions were puriﬁed using a QIAquick PCR Puriﬁ-
cation Kit (Qiagen, Chatsworth, CA) before cloning. This
approach produced a spectrum of clones representative of
all band species and their relative frequencies within a par-
ticular spectratype PCR reaction. DNA sequence analysis
of clones was performed using a Taq Dye Deoxy-Terminator
Cycle Sequencing Kit (Applied Biosystems, Foster City,
CA). We deﬁned each unique TCR BV CDR3 nucleotide
sequence determined in this manner as a “TCR BV clono-
type” or simply “clonotype.”
Electroblot hybridization. Oligonucleotide clonotype-spe-
cific probes to TCR CDR3 regions of interest were
designed based on the DNA sequence of predominant
CDR3 regions. The sequences for the probes used are
underlined in Figure 2. Each clonotype-speciﬁc probe was
radiolabeled using [32P]ATP (Dupont NEN, Boston, MA),
polynucleotide kinase, and end-labeling buffer according to
manufacturer recommendation (New England Biolabs, Bev-
erly, MA). Spectratypes were electroblotted from acrylamide
gels onto positively charged nylon membranes (Boehringer
Mannheim, Indianapolis, IN) and ultraviolet (UV) cross-
linked using the auto cross-link setting on a Stratalinker UV
1800 (Stratagene, La Jolla, CA). Electroblots were subse-
quently hybridized overnight with agitation at 42°C with a
[32P]-labeled clonotype-specific probe in 10× Denhardt’s
solution, 5× sodium chloride and sodium citrate (SSC) (1×
SSC is NaCl 0.15 mol/L, Na3 citrate · 2H2O 0.0015 mol/L,
pH 7.0), 7% sodium dodecyl sulfate (SDS), 20 mmol/L
Na2HPO4, and 100 µg/mL denatured herring sperm DNA.
After hybridization, the electroblots were washed twice for
10 minutes at 42°C in 3× SSC, 5% SDS, and 70 mmol/L
phosphate buffer, pH 7.0, followed by 2 additional washes at
42°C in 1× SSC and 1% SDS. After a brief rinse in 2× SSC,
the electroblots were subjected to autoradiography and ana-
lyzed using a Molecular Dynamics PhosphoImager.
Figure 1. Spectratyping and clonotyping methodologies. The spectratyping method uses complementarity-determining region 3 (CDR3) length
heterogeneity to characterize the T-cell repertoire. The clonotyping method uses CDR3 region sequencing to monitor a particular CDR3 sequence
of interest in different samples. cDNA indicates complementary DNA; PCR, polymerase chain reaction; bp, base pair; mRNA, messenger RNA.
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RESULTS
Histology
Figure 3A shows a hematoxylin and eosin stain of the
liver biopsy. The biopsy showed the characteristic appear-
ance of aGVHD, with a mild lymphocytic inﬁltrate of the
portal triad and intra-epithelial extension into duct epithe-
lium. Immunohistochemistry stains for CD8 (Figure 3B)
and CD4 (Figure 3C) demonstrated that the lymphocytic
inﬁltrate was primarily CD8+.
T-Cell Repertoire Analysis
Spectratyping was done to evaluate and compare the
T-cell repertoire of the blood and liver compartments. At
the time of the liver GVHD, the patient had reconstituted a
complex peripheral blood T-cell repertoire as evidenced by
the presence of CDR3 length heterogeneity in almost all the
T-cell families. The repertoire complexity was skewed in a
number of families (Figure 4). In variable gene beta (VΒ) 4,
VΒ7, and VΒ8 (* in Figure 4), an oligoclonal expansion was
seen in both the peripheral blood and liver compartments.
The skewed pattern VΒ15 and VΒ5.3 (# in Figure 4) was
seen only in the peripheral blood compartment.
Sequence Analysis
Based on the spectratype data, we assessed, using DNA
sequencing, whether the limited T-cell repertoire present in
the liver biopsy sample was due to a tissue-specific T-cell
expansion or simply peripheral blood contamination. We
noted the relevant expansions by spectratype and developed
specific probes for the predominant CDR3 sequences
detected. Sequencing was done for VΒ7, VΒ4, and VΒ8
because they were present in both liver and blood T-cell
repertoires. Sequencing was also done for VΒ15 and
VΒ5.3 because they were present in only the peripheral
blood T-cell repertoire. These particular families were cho-
sen because they had the strongest relative intensities by
spectratype analysis. Based on the predominant CDR3
sequences identiﬁed, clonotype-speciﬁc probes were made.
These sequences and the relevant clonotype probes are
illustrated in Figure 2.
Clonotype Probe Analysis
Figure 5A and B shows the results of the clonotype probe
analysis for the predominant CDR3 sequence in VΒ15 and
VΒ5.3. By spectratype analysis, these were found in only the
blood compartment. The results of the probing experiments
showed that the predominant clonotypes found in the blood
were not present in the liver. These data exclude the possibil-
ity that the expansions in the liver were due to blood contam-
ination from the time of the biopsy. Both of the predominant
clonotypes remained present over time, as evidenced by their
presence in the blood at the second time point, 17 months
after the transplantation. Both clonotypes were present in the
donor samples of blood and bone marrow, as well as in the
T-cell line that was grown from cells circulating in the
peripheral blood during the time of skin GVHD.
Figure 5C and D shows the results of the clonotype
probe analysis for the predominant CDR3 sequence of VΒ4
and VΒ7. By spectratype, these families were present in the
liver and blood compartments. In these instances, the
Figure 2. Predominant complementarity-determining region 3 (CDR3)
sequences with subsequent probe sequences used for clonotyping. The
top lines indicates the V-J combination. The second line is the amino
acid sequence encoded. The third line shows the nucleotide sequence.
The N-D-N portion of the CDR3 region is underlined. The last line
shows the clonotype probe used to identify the unique clonotype.
Figure 3. Biopsy sample taken at the time of liver acute graft-versus-host disease. A. Standard hematoxylin and eosin stain. B. Immunohistochem-
istry stain for CD8. C. Immunohistochemistry stain for CD4.
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predominant clonotype was seen in both the liver and the
initial blood time point. The VΒ7 clonotype was seen at the
second time point. It was also present in the donor samples; it
was not well visualized in the T-cell line. The VΒ4 clonotype
was not seen at the second peripheral blood time point, and it
was not well seen in the donor samples or the T-cell line.
Figure 5E shows the clonotype analysis for the predom-
inant VΒ8 clonotype. In contrast to the other CDR3
sequences, this clonotype was present in the liver, both
peripheral blood time points, and the T-cell line. It was also
a clonotype present in the donor, since it was visualized in
donor blood and bone marrow. The negative control was
blank, excluding laboratory error as an explanation for the
clonotype’s presence in so many samples.
DISCUSSION
This clinical case, together with the laboratory data,
provides insight into the pathobiology of acute GVHD in
the matched sibling setting. In this instance, the patient
developed severe yet controllable skin aGVHD at the time
of engraftment; it was not accompanied by clinical evidence
of liver or bowel aGVHD. However, the patient developed
isolated liver aGVHD at a later date while immunosuppres-
sion was being decreased. The clinical history and previous
work done in the field provided a foundation for the
hypothesis that T-cell inﬁltrates within a liver biopsy taken
at the time of liver GVHD would show a restricted T-cell
response. We additionally hypothesized that, because there
was such a marked time lag between manifestations of the
skin and liver GVHD, the effectors responsible for liver
aGVHD may be different from those in skin aGVHD.
The presence of CD8+ cells in the cellular inﬁltrate at the
time of the liver biopsy provided the initial evidence support-
ing the concept that a T-cell inﬁltrate was causing liver dam-
age. The liver biopsy was compatible with aGVHD (Fig-
ure 3). The clinical picture was more confusing, however,
because the patient had transaminase elevation instead of an
increase in serum bilirubin, the characteristic sign of liver
GVHD. This clinical picture has been observed in other
patients as immunosuppression is decreased [6]. It is interest-
ing to note that most of the cells stained positive for CD8.
Because the patient and donor were matched siblings, it is
reasonable to assume that minor histocompatibility antigens
were the trigger for the CD8+ response seen in the liver.
The laboratory data illustrated in Figure 4 show that in
the peripheral blood compartment, the patient had reconsti-
tuted a complex T-cell repertoire that included T-cell fami-
lies with apparent oligoclonal expansion, as demonstrated by
skewing of the T-cell repertoire. Post-BMT alterations in
the circulating T-cell repertoire may be attributable to a
number of variables, including intercurrent infections, use
of immunosuppressive drugs, and acute GVHD [7]. How-
ever, the presence of the T-cell inﬁltrate in the liver during
clinical aGVHD suggests that at least a portion of the
peripheral blood T-cell expansions were due to effectors of
the liver GVHD response.
The sequence of the predominant CDR3 regions corre-
sponding to the skewed T-cell repertoire provides a more
precise method to determine if a particular T cell with a
deﬁned CDR3 sequence is present in a sample [3]. According
to this methodology, the data in Figure 5 demonstrate that
the oligoclonal sequences using VΒ4 and VΒ7 were present
in the liver as well as the peripheral blood. The data showing
that the expanded clonotypes using VΒ15 and VΒ5.3 were
present in the blood but not the liver demonstrate that not
all T cells that had expanded in the peripheral blood were
inﬁltrating the liver. These ﬁndings rule out simple periph-
eral blood circulation or surgical contamination as the reason
for oligoclonal T-cell expansion in the liver (in which case all
the expansions seen within the blood would have been seen
within the liver compartment). Therefore, the data suggest
that a limited, tissue-speciﬁc T-cell inﬁltrate was responsible
for the observed clinical condition of acute liver GVHD. We
cannot formally exclude the possibility that our observations
are due to organ-specific lymphocyte trafficking, however,
because we do not have healthy control samples of paired
liver biopsy and peripheral blood samples.
An intriguing part of this clinical history is that at differ-
ent times there were different end organs showing symp-
toms of aGVHD. Our laboratory data lend some insight
into this observation. The data show that different T-cell
expansions in the blood correspond with different sites of
GVHD. The clinical observation is coincident with the lab-
oratory data in Figure 5, which show that the clonotypes
expanded in the peripheral blood but not the liver (VΒs 5.3
and 15) were present in the T-cell line made from cells
Figure 4. Spectratypes. Samples comparing the liver biopsy sample (lane
2) and the peripheral blood compartment (lane 3) with negative (water)
(lane 1) and positive (lane 4) controls. The positive control is from a nor-
mal pool blood donor.
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circulating in the peripheral blood at the time of skin
aGVHD. These findings suggest that these T cells were
involved in the anti-skin GVHD response. We recognize that
only a skin biopsy could prove this point beyond doubt [8];
because of the serious clinical situation at the time of skin
GVHD, a biopsy was not taken. The patient did not develop
bowel GVHD, so no bowel biopsies were performed.
The finding of a limited T-cell infiltrate in the liver,
together with data showing that these cells did not appear to
be present in a T-cell line at the time of skin GVHD, leads
to the question: To what are the effector cells responding
within the liver? We have no formal data to answer this ques-
tion. Because this case took place in the matched-sibling





Figure 5. Spectratypes and clonotypes. The spectratype and subsequent clonotype blot for VBs 15 (A), 5.3 (B), 4 (C), 7 (D), and 8 (E). Lane 1, plas-
mid (positive control); lane 2, water (negative control); lane 3, liver biopsy sample; lane 4, peripheral blood at the time of liver graft-versus-host dis-
ease (GVHD); lane 5, peripheral blood 17 months after transplantation; lane 6, donor marrow; lane 7, donor peripheral blood mononuclear cells;
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histocompatibility antigens. That there appears to be a tis-
sue-speciﬁc inﬁltrate leads us to speculate that the targets for
these T cells are tissue-specific minor antigens. Prior
research by others supports this speculation. Experiments
done by Howell et al. [9] suggest that murine GVHD is
caused by cells that are sensitized to minor histocompatibil-
ity antigens expressed by host biliary epithelial cells. Howell
et al. [10] also observed that adhesion molecules expressed by
bile duct epithelial and portal vein endothelial cells play a
role in the minor histocompatibility barrier causing experi-
mental GVHD. This concept has been evaluated in humans.
Miglio et al. [11] found that 6 of 6 patients with GVHD had
major histocompatibility complex (MHC) class II expression
on intrahepatic bile ducts, whereas 4 of 4 patients without
GVHD had no evidence of MHC class II expression on their
bile ducts. Taken together, our data support the concept that
hepatic GVHD is caused by a limited number of effectors
responding to a limited number of antigens.
In contrast to the other data, the VΒ8 clonotype is pres-
ent in the liver, the T-cell line, and at both time points in
the peripheral blood. Why this clonotype showed a different
pattern than the others remains unknown. We do not
believe it is laboratory error, since the negative controls sug-
gested no laboratory contamination. We interpret the data
from VΒ8 to suggest that there may be overlap between
T cells in different compartments, particularly if the antigen
triggering the effector cells was present in more than 1 com-
partment. Therefore, it is possible that this clonotype was
responding to a ubiquitously expressed minor histocompati-
bility antigen, not a tissue-specific minor antigen, since it
was identiﬁed in the liver compartment and the T-cell line
developed from cells circulating at the time of skin GVHD.
Because the donor in this case was female and the patient
male, the response may be a manifestation of a donor-
derived, anti-recipient, anti–H-Y antigen response. Data
generated by Johnston and Wettstein [12] support the idea
that there may be a restricted repertoire of effector cells
responding to the H-Y antigen.
The data in Figure 5 also give insight into immune recon-
stitution after a T-cell–replete BMT. Most of the clonotypes
had enough precursors in the donor’s blood and infused bone
marrow samples to be identiﬁed by the clonotyping proce-
dure. This means that the same CDR3 sequences were used
by the donor and the recipient. Additionally, some clonotypes
had continued relative expansion over time (VΒs 8, 5.3, and
15), whereas others decreased their portion of the repertoire
(VΒ7 and VΒ4). These data are consistent with the view of
immune reconstitution supported by Mackall et al. [13]. In
studies using transgenic mice, Mackall et al. have determined
that T-cell regeneration in thymic-deficient hosts occurs
largely via TCR/MHC-mediated selection of peripheral T-cell
populations. They conclude that this process results in a
T-cell repertoire composed exclusively of T cells recently acti-
vated by the antigenic milieu of the host, with negligible num-
bers of naive cells bearing TCRs for antigens absent at the
time of expansion. Our interpretation of our data, in the con-
text of the hypothesis of Mackall et al., is that during the acute
GVHD response there is clonal expansion of donor-derived
T cells responding to tissue-speciﬁc minor histocompatibility
antigens. We can only speculate as to why some of the families
remained skewed and expanded over time and others did not.
The liver-speciﬁc bands, VΒ4 and VΒ7, were not expanded at
the second time point, which was during a mild transaminase
elevation that resolved without intervention. This leads us to
speculate that the second clinical transaminase elevation was
not due to the same mechanisms as the ﬁrst one. Why the
VΒ5.3, VB15, and VB8 repertoire remained skewed with the
predominant clonotypes present over time is also unclear. We
speculate that the antigens driving these portions of the reper-
toire, such as possibly the H-Y antigen in VΒ8, continued to
provide antigenic stimulation.
In summary, this clinical case, with supporting basic sci-
entiﬁc data, shows that in clinical hepatic GVHD there can
be a focal T-cell inﬁltrate that shows a limited T-cell reper-
toire. Further studies focusing on elucidating the antigenic
triggers for this limited T-cell response will be helpful in
designing preventive and therapeutic strategies. Clearly,
nonspecific immunosuppression leaves the host at signifi-
cant risk for developing infections and other post-BMT
complications such as posttransplantation lymphomas. Our
data support the concept that clinical GVHD may be due
to a limited number of effectors. Consequently, focused and
therefore safer immunosuppression should be feasible.
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